- Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
- Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
- Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
- Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
- Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
- Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
- Alto Neuroscience to Participate in Upcoming Investor Conferences
- Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.30 |
---|---|
High | 12.55 |
Low | 12.29 |
Bid | 12.48 |
Offer | 12.59 |
Previous close | 12.28 |
Average volume | 104.96k |
---|---|
Shares outstanding | 26.88m |
Free float | 23.36m |
P/E (TTM) | -- |
Market cap | 330.14m USD |
EPS (TTM) | -1.90 USD |
Data delayed at least 15 minutes, as of May 23 2024 16:53 BST.
More ▼